3 results
Not approvedWill not start
reduction of fluid administration of 30%
Approved WMORecruiting
Primary Objective: 1) To evaluate the efficacy of DTX301 on the improvement of OTC function by maintaining safe plasma ammonia levelsSecundary Objective:1) To evaluate the efficacy of DTX301 in 3 response categories2) To evaluate the effect of…
Approved WMORecruiting
The pivotal Phase III NETTER-1 study showed that Lutathera with best supportive care (30mg octreotide long-acting) provided a significant increase in PFS to patients with progressive midgut carcinoid tumors (at enrollment) compared to patients…